Nicht lieferbar
Andere Kunden interessierten sich auch für
High Quality Content by WIKIPEDIA articles! Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP). Rib-X Pharmaceuticals, Inc. is a privately-held New Haven, Connecticut based development-stage biopharmaceutical company, founded in 2001 to develop small-molecule antibiotics to treat serious multi-drug resistant bacterial infections. Rib-X's compounds (two of which are in Phase 2 clinical trials) include those that may treat many of the pathogens on the 2006 IDSA hit list of dangerous microbes, including Methicillin-resistant Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.